Refine by
Fetal Harm Equipment & Supplies
6 equipment items found
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
TALICIA is an oral, all-in-one capsule containing omeprazole, amoxicillin, and rifabutin that is indicated for the treatment of Helicobacter pylori infection in ...
Manufactured by:Pfizer Inc. based in, NEW YORK (USA)
These highlights do not include all the information needed to use ALFENTANIL INJECTION safely and effectively. See full prescribing information for ALFENTANIL ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: BELRAPZO® (bendamustine hydrochloride injection) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. BELRAPZO® (bendamustine hydrochloride injection) is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease has not progressed after four ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: BENDEKA® is indicated for the treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality ...